PE20071003A1 - Formulacion de suspension de fexofenadina - Google Patents

Formulacion de suspension de fexofenadina

Info

Publication number
PE20071003A1
PE20071003A1 PE2006001593A PE2006001593A PE20071003A1 PE 20071003 A1 PE20071003 A1 PE 20071003A1 PE 2006001593 A PE2006001593 A PE 2006001593A PE 2006001593 A PE2006001593 A PE 2006001593A PE 20071003 A1 PE20071003 A1 PE 20071003A1
Authority
PE
Peru
Prior art keywords
approximately
dihydrate
less
fexofenadine
suspension formulation
Prior art date
Application number
PE2006001593A
Other languages
English (en)
Spanish (es)
Inventor
Prafulla Agrawala
Kazimierz Chrzan
Rajiv Haribhakti
Matthew Mermey
Curtis J Porcello
Gary Lee Silvey
Vinh Tran
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38120312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20071003(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of PE20071003A1 publication Critical patent/PE20071003A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
PE2006001593A 2005-12-14 2006-12-12 Formulacion de suspension de fexofenadina PE20071003A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75030305P 2005-12-14 2005-12-14

Publications (1)

Publication Number Publication Date
PE20071003A1 true PE20071003A1 (es) 2007-10-03

Family

ID=38120312

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001593A PE20071003A1 (es) 2005-12-14 2006-12-12 Formulacion de suspension de fexofenadina

Country Status (38)

Country Link
US (1) US8933097B2 (https=)
EP (1) EP1965768B1 (https=)
JP (1) JP5308824B2 (https=)
KR (1) KR101452792B1 (https=)
CN (1) CN101316580B (https=)
AR (1) AR058323A1 (https=)
AT (1) ATE431137T1 (https=)
AU (1) AU2006326551B2 (https=)
BR (1) BRPI0619895B1 (https=)
CA (1) CA2633086C (https=)
CR (1) CR9993A (https=)
CY (1) CY1109320T1 (https=)
DE (1) DE602006006870D1 (https=)
DK (1) DK1965768T3 (https=)
DO (1) DOP2006000274A (https=)
EC (1) ECSP088532A (https=)
EG (1) EG25866A (https=)
ES (1) ES2327168T3 (https=)
HN (1) HN2008000875A (https=)
HR (1) HRP20090411T1 (https=)
IL (1) IL192067A (https=)
JO (1) JO2549B1 (https=)
MA (1) MA30152B1 (https=)
MY (1) MY146988A (https=)
NO (1) NO339877B1 (https=)
NZ (1) NZ568943A (https=)
PE (1) PE20071003A1 (https=)
PL (1) PL1965768T3 (https=)
PT (1) PT1965768E (https=)
RS (1) RS51135B (https=)
RU (1) RU2405538C2 (https=)
SI (1) SI1965768T1 (https=)
TN (1) TNSN08186A1 (https=)
TW (1) TWI377061B (https=)
UA (1) UA89584C2 (https=)
UY (1) UY30021A1 (https=)
WO (1) WO2007070517A2 (https=)
ZA (1) ZA200803985B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101546774B1 (ko) 2008-07-29 2015-08-24 엘지전자 주식회사 휴대 단말기 및 그 동작제어 방법
CA2852447A1 (en) 2011-10-19 2013-04-25 R.P. Scherer Technologies, Llc Two phase pharmaceutical delivery system
US10130620B2 (en) 2013-07-01 2018-11-20 Aventisub Llc Liquid pharmaceutical composition for oral administration comprising fexofenadine
BR112015032791A2 (pt) * 2013-07-03 2017-07-25 Scherer Technologies Llc R P composição para uso como enchimento de cápsula, e, cápsula
CN103610645B (zh) * 2013-11-25 2016-05-11 浙江万晟药业有限公司 一种非索非那定盐酸盐的药物组合物及制备方法
CN106806346B (zh) * 2015-12-01 2020-09-11 国药集团广东环球制药有限公司 一种非索非那定盐酸盐干混悬剂制剂及其制备方法
ES3014923T3 (en) 2016-06-16 2025-04-28 Azurity Pharmaceuticals Inc Composition and method for proton pump inhibitor suspension
EP3639812A4 (en) 2017-06-02 2021-03-17 Teika Pharmaceutical Co., Ltd. SOLUBILIZED MICELLA CONSISTING OF A LOW SOLUBLE COMPONENT AND SOLUTION CONTAINING IT
US11633478B2 (en) 2019-07-16 2023-04-25 Azurity Pharmaceuticals, Inc. Compositions and kits for Omeprazole suspension
US10751333B1 (en) 2019-07-16 2020-08-25 Cutispharma, Inc. Compositions and kits for omeprazole suspension
EP4199980A1 (en) * 2020-08-18 2023-06-28 Innate S.r.l. Injectable composition and use of said composition
WO2022175829A1 (en) 2021-02-17 2022-08-25 Cellix Bio Private Limited Topical formulations and compositions
AU2021480621A1 (en) * 2021-12-29 2024-07-18 Opella Healthcare Group Sas Compositions containing fexofenadine
CN115715759B (zh) * 2022-11-03 2024-01-12 京海盛达(北京)科技有限公司 一种抗组胺混悬剂及其制备方法
EP4651852A1 (en) 2023-01-20 2025-11-26 Opella Healthcare Group SAS Paraben-free fexofenadine formulations
WO2026074306A1 (en) 2024-10-03 2026-04-09 Opella Healthcare Group Sas Chewable fexofenadine tablets

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4829064A (en) 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
CN1148849A (zh) * 1994-05-18 1997-04-30 赫彻斯特马里恩鲁斯公司 抗组胺哌啶衍生物,其多晶形物和假同晶物的无水和水合物形式的制备方法
US6132758A (en) 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
US6319513B1 (en) * 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
GB9822170D0 (en) 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
WO2003011295A1 (en) 2001-07-31 2003-02-13 Texcontor Etablissement Fexofenadine polymorph
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
CA2514570C (en) * 2003-01-30 2011-09-06 Ethypharm Taste-masking coated particles, process for the preparation thereof and orodispersible tablets containing said coated particles
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20050266031A1 (en) 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
DK2377557T3 (en) * 2004-11-24 2017-02-06 Meda Pharmaceuticals Inc Compositions comprising azelastine and methods for its use
CN101228128A (zh) 2005-07-27 2008-07-23 桑多斯股份公司 一种用于制备取代苯基醚化合物和罗西格列酮的方法
JP5133244B2 (ja) * 2005-08-05 2013-01-30 ルピン・リミテッド フェキソフェナジンの経口用医薬懸濁組成物

Also Published As

Publication number Publication date
PT1965768E (pt) 2009-08-07
DK1965768T3 (da) 2009-09-07
WO2007070517A2 (en) 2007-06-21
UY30021A1 (es) 2007-07-31
DOP2006000274A (es) 2007-10-15
JP5308824B2 (ja) 2013-10-09
JP2009519935A (ja) 2009-05-21
HN2008000875A (es) 2012-01-30
UA89584C2 (en) 2010-02-10
TW200812581A (en) 2008-03-16
IL192067A0 (en) 2009-02-11
DE602006006870D1 (de) 2009-06-25
NZ568943A (en) 2010-04-30
KR101452792B1 (ko) 2014-10-22
US20080299211A1 (en) 2008-12-04
CA2633086A1 (en) 2007-06-21
ES2327168T3 (es) 2009-10-26
ATE431137T1 (de) 2009-05-15
MY146988A (en) 2012-10-15
RU2405538C2 (ru) 2010-12-10
BRPI0619895B1 (pt) 2022-04-12
SI1965768T1 (sl) 2009-10-31
WO2007070517A3 (en) 2007-08-23
TNSN08186A1 (en) 2009-10-30
CA2633086C (en) 2011-10-18
CN101316580B (zh) 2011-11-16
ZA200803985B (en) 2009-03-25
CN101316580A (zh) 2008-12-03
RS51135B (sr) 2010-10-31
TWI377061B (en) 2012-11-21
ECSP088532A (es) 2008-08-29
IL192067A (en) 2010-12-30
CY1109320T1 (el) 2014-07-02
JO2549B1 (en) 2010-09-05
AU2006326551B2 (en) 2012-06-07
CR9993A (es) 2008-09-23
EP1965768A2 (en) 2008-09-10
KR20080074180A (ko) 2008-08-12
US8933097B2 (en) 2015-01-13
RU2008128418A (ru) 2010-01-20
BRPI0619895A2 (pt) 2011-10-25
NO20082904L (no) 2008-09-10
AR058323A1 (es) 2008-01-30
HK1123197A1 (en) 2009-06-12
MA30152B1 (fr) 2009-01-02
HRP20090411T1 (hr) 2010-01-31
PL1965768T3 (pl) 2009-11-30
EG25866A (en) 2012-09-12
AU2006326551A1 (en) 2007-06-21
EP1965768B1 (en) 2009-05-13
NO339877B1 (no) 2017-02-13

Similar Documents

Publication Publication Date Title
PE20071003A1 (es) Formulacion de suspension de fexofenadina
CL2019000209A1 (es) Formulación novedosa administrable por la vía oral.
CU23850B1 (es) Composiciones farmacéuticas estabilizadas que comprenden fesoterodina
GT200600295AA (es) Una formulacion solida de dosificacion farmaceutica (patente fraccionaria derivada de la solicitud de patente no. pi-2006-295)
DK1553927T3 (da) Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger
ES2194732T3 (es) Composiciones farmaceuticas orales de liberacion controlada de mesalazina.
AR071852A1 (es) Formulacion farmaceutica de un anticuerpo frente a ox40l
CO5170479A1 (es) Emulsion aceite en agua que comprende un agente biologicamente activo micronizado y un sistema emulsionante adecuado saturado y un mono de ester de acido acrilico. .
CL2012001310A1 (es) Composicion que comprende un oligopeptido ciclo-(arg-gly-asp-dphe-nmeval) que tiene una solubilidad en agua a 20ºc de entre 1 mg/ml y 20 mg/ml y con uno o varios compuestos lipofilicos y/o anfifílicos; proceso para preparar dicha composicion.
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
CL2019001366A1 (es) Formulaciones tamponadas exendina (9-39).
CO6270217A2 (es) Formulaciones galenicas de alisquireno y valsartan
CL2008000610A1 (es) Composicion en forma de dosificacion transdermica o transmucosa que comprende una relacion en peso de buprenorfina a naloxona entre 2,1:1 y 8:1, util para el tratamiento del dolor.
AR061351A1 (es) Composicion de carbamato de bencimidazol
UY38055A (es) Composiciones oftálmicas de compuestos de bencimidazol para uso unico diario
BRPI0821373B8 (pt) composições farmacêuticas contendo ao menos um princípio ativo protéico protegido de enzimas digestivas
AR075180A1 (es) Formulaciones orales solidas de una pirido-pirimidinona
PE20070377A1 (es) Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
AR061802A1 (es) Composicion que tiene una actividad que previene la germinacion, procedimientos para obtener dichas composiciones y uso de las mismas
WO2007008778A3 (en) Formulations for enhanced mucosal delivery of pyy
ES2325291A1 (es) "uso de un extracto de silybum marianum"
MX2020009318A (es) Formulación gastroprotegida e hidrófoba de al menos un principio activo y método para obtener la misma.
CL2007001763A1 (es) Composicion farmaceutica en forma de una tableta multicapas que comprende una primera region que comprende una tetraciclina y un vehiculo, y una segunda region que comprende un tampon y un segundo vehiculo; formulacion acuosa; y uso para tratar o prevenir la mucositis oral.
PE20050359A1 (es) Composiciones topicas que comprenden terbinafina e hidrocortisona
UY29403A1 (es) Composiciones farmacéutica sólida que comprende telitromicina.

Legal Events

Date Code Title Description
FC Refusal